tradingkey.logo

Sonoma Pharmaceuticals Inc

SNOA
3.760USD
-0.020-0.53%
Close 11/04, 16:00ETQuotes delayed by 15 min
6.18MMarket Cap
LossP/E TTM

Sonoma Pharmaceuticals Inc

3.760
-0.020-0.53%

More Details of Sonoma Pharmaceuticals Inc Company

Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.

Sonoma Pharmaceuticals Inc Info

Ticker SymbolSNOA
Company nameSonoma Pharmaceuticals Inc
IPO dateJan 26, 2007
CEOMs. Amy Trombly
Number of employees168
Security typeOrdinary Share
Fiscal year-endJan 26
Address5445 Conestoga Court, Suite 150
CityBOULDER
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code80301
Phone18007599305
Websitehttps://sonomapharma.com/
Ticker SymbolSNOA
IPO dateJan 26, 2007
CEOMs. Amy Trombly

Company Executives of Sonoma Pharmaceuticals Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Jay E. Birnbaum, Ph.D.
Dr. Jay E. Birnbaum, Ph.D.
Independent Director
Independent Director
286.00
-0.35%
Mr. Jerry G. Mclaughlin
Mr. Jerry G. Mclaughlin
Lead Independent Director
Lead Independent Director
--
--
Mr. Philippe Weigerstorfer
Mr. Philippe Weigerstorfer
Independent Director
Independent Director
--
--
Mr. Jerry Dvonch
Mr. Jerry Dvonch
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Amy Trombly
Ms. Amy Trombly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jay E. Birnbaum, Ph.D.
Dr. Jay E. Birnbaum, Ph.D.
Independent Director
Independent Director
286.00
-0.35%
Mr. Jerry G. Mclaughlin
Mr. Jerry G. Mclaughlin
Lead Independent Director
Lead Independent Director
--
--
Mr. Philippe Weigerstorfer
Mr. Philippe Weigerstorfer
Independent Director
Independent Director
--
--
Mr. Jerry Dvonch
Mr. Jerry Dvonch
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Amy Trombly
Ms. Amy Trombly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Human Care
3.56M
88.54%
Animal Care
460.00K
11.46%
By RegionUSD
Name
Revenue
Proportion
Europe
1.47M
36.56%
United States
1.00M
25.03%
Asia
662.00K
16.49%
Latin America
564.00K
14.05%
Rest of the world
316.00K
7.87%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Human Care
3.56M
88.54%
Animal Care
460.00K
11.46%

Shareholding Stats

Updated: Thu, Oct 23
Updated: Thu, Oct 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Heron Bay Capital Management, LLC
2.05%
The Vanguard Group, Inc.
1.14%
Renaissance Technologies LLC
1.08%
Geode Capital Management, L.L.C.
1.07%
UBS Financial Services, Inc.
0.87%
Other
93.79%
Shareholders
Shareholders
Proportion
Heron Bay Capital Management, LLC
2.05%
The Vanguard Group, Inc.
1.14%
Renaissance Technologies LLC
1.08%
Geode Capital Management, L.L.C.
1.07%
UBS Financial Services, Inc.
0.87%
Other
93.79%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.10%
Individual Investor
1.28%
Hedge Fund
1.14%
Investment Advisor/Hedge Fund
1.07%
Other
92.42%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
33
104.13K
6.31%
+23.01K
2025Q2
39
61.63K
4.65%
-24.83K
2025Q1
40
54.41K
3.31%
-8.75K
2024Q4
40
41.45K
2.57%
-24.32K
2024Q3
41
49.08K
3.40%
+9.77K
2024Q2
40
43.04K
3.61%
+17.90K
2024Q1
38
20.55K
2.85%
-9.28K
2023Q4
36
27.53K
4.02%
+7.17K
2023Q3
35
18.63K
7.25%
-6.00K
2023Q2
37
18.70K
7.42%
+4.13K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Heron Bay Capital Management, LLC
33.78K
2.05%
+33.78K
--
Jun 30, 2025
The Vanguard Group, Inc.
18.79K
1.14%
--
--
Aug 31, 2025
Renaissance Technologies LLC
17.80K
1.08%
+17.80K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
17.62K
1.07%
+812.00
+4.83%
Jun 30, 2025
UBS Financial Services, Inc.
14.42K
0.87%
+12.56K
+678.46%
Jun 30, 2025
Thornton (Bruce)
7.72K
0.47%
-1.00
-0.01%
Jul 08, 2025
Trombly (Amy Moss)
7.68K
0.47%
--
--
Jul 08, 2025
Dvonch (Jerome J)
4.23K
0.26%
-1.00
-0.02%
Jul 08, 2025
Tower Research Capital LLC
1.00K
0.06%
-447.00
-30.89%
Jun 30, 2025
Dal (Poggetto John)
910.00
0.06%
+910.00
--
Jun 20, 2024
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
Date
Type
Ratio
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
Aug 28, 2024
Merger
20→1
KeyAI